Loperamide reverses 5‑FU resistance in colorectal cancer by activating autophagy.

ABSTRACT: 5‑Fluorouracil (5‑FU), a cornerstone chemotherapeutic agent used for colorectal cancer therapy, has long been established as a first‑line treatment. However, clinical evidence has suggested that a substantial proportion of patients develop resistance to 5‑FU, notably compromising its therapeutic efficacy. The present study aimed to investigate whether loperamide (LOP) can enhance the sensitivity of colorectal cancer cells to 5‑FU and to elucidate the potential underlying molecular mechanism. First, the IC₅₀ values of LOP were determined in the 5‑FU‑sensitive HCT8 and 5‑FU‑resistant HCT8R colorectal cancer cell lines, using the Cell Counting Kit‑8 assay to evaluate LOP‑induced alterations in 5‑FU sensitivity. The effects of LOP on cell proliferation were subsequently analyzed usi

SUBMITTER: Yu J 

PROVIDER: S-EPMC12340758 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature